We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.42B
1-Year Est. Return
34.72%
This Fund
S&P 500
This Quarter
Est. Return
-5.04%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$1.34B
AUM Growth
-$83.7M
(-5.9%)
Cap. Flow
+$6.76M
Cap. Flow
% of AUM
0.51%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$6.76M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 39.99% |
| 2 | Healthcare | 39.26% |
| 3 | Industrials | 11.09% |
Similar funds
PTC
NI
CBA
KC
EWS
IHG
SCM
PPC
Broadwood Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Broadwood Capital held 7 positions worth $1.34B, down 5.9% from $1.42B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q2 2023: portfolio turnover was 0%. Broadwood Capital opened no new positions and made no exits, leaving the 7-position portfolio largely intact.
By sector, the portfolio is most concentrated in Consumer Staples at 40% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.
- Broadwood Capital added most to Insight Molecular Diagnostics in Q2 2023, an estimated $6.76M increase.
- Broadwood Capital's ten largest holdings make up 100% of its $1.34B portfolio in Q2 2023.
- Broadwood Capital opened 0 new positions and closed 0 in Q2 2023.
- Broadwood Capital's portfolio value fell 5.9% quarter-over-quarter to $1.34B.
Based on Broadwood Capital's 13F filing for Q2 2023, filed 14 Aug 2023.